Histamine-2 receptor antagonists and gastric cancer

Epidemiology. 1996 Jul;7(4):434-6. doi: 10.1097/00001648-199607000-00016.

Abstract

We conducted a case-control study at Group Health Cooperative of Puget Sound to evaluate the relation between longterm histamine-2 (H2) receptor antagonist use and gastric cancer. We identified 113 cases and 452 controls and estimated a relative risk (RR) of 2.0 [95% confidence interval (C1) = 1.0-3.9]. When we evaluated the effect of time-since-first-use, the RR estimates were 6.5, 1.2, and 1.0 for 2-4 years of use, 5-9 years, and > or = 10 years, respectively. The data provide substantial evidence that long-term H2 antagonist use is not associated with gastric cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Cimetidine / adverse effects*
  • Female
  • Histamine H2 Antagonists / adverse effects*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Ranitidine / adverse effects*
  • Regression Analysis
  • Retrospective Studies
  • Risk Factors
  • Stomach Neoplasms / chemically induced*
  • Stomach Neoplasms / epidemiology
  • Stomach Neoplasms / pathology
  • Washington / epidemiology

Substances

  • Histamine H2 Antagonists
  • Cimetidine
  • Ranitidine